{"id":1943,"date":"2026-11-09T13:56:56","date_gmt":"2026-11-09T13:56:56","guid":{"rendered":"https:\/\/baarda.ch\/?p=1943"},"modified":"2026-11-09T13:56:56","modified_gmt":"2026-11-09T13:56:56","slug":"reint-jelger-hi-gem-novartis-sort-of-seems-like-a-big-company-is-it-useful-novartis-exists-what-would-earth-be-like-if-they-didnt-exist","status":"publish","type":"post","link":"https:\/\/baarda.ch\/?p=1943","title":{"rendered":"Reint Jelger: Hi Gem, Novartis sort of seems like a big company. Is it useful Novartis exists? What would earth be like if they didn\u2019t exist?"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-41.png\" alt=\"\" class=\"wp-image-1946\" srcset=\"https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-41.png 1024w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-41-300x168.png 300w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-41-768x429.png 768w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-41-500x279.png 500w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Google Gemini: Novartis is the third-largest pharmaceutical company in Europe by market value (behind Novo Nordisk and Roche) and consistently ranks among the top 10 globally. With annual revenues around $45\u201350 billion and a market capitalization exceeding $200 billion, it operates as a major pillar of global healthcare and industrial medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. Core Medical &amp; Economic Contributions<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis affects global health and industrial research primarily through three avenues:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Life-Saving Therapeutics:<\/strong> It produces critical therapies across oncology, cardiovascular health, immunology, and neuroscience. Flagship drugs include <strong>Entresto<\/strong> (standard-of-care heart failure treatment reducing cardiovascular death risks by ~20%), <strong>Cosentyx<\/strong> (psoriasis and ankylosing spondylitis), and <strong>Gleevec\/Glivec<\/strong> (imatinib), which fundamentally transformed Chronic Myeloid Leukemia (CML) from a fatal diagnosis into a manageable chronic condition.<\/li>\n\n\n\n<li><strong>Pioneering Advanced Modalities:<\/strong> Novartis leads early-stage commercialization in cell and gene therapies, including <strong>Kymriah<\/strong> (the first FDA-approved CAR-T cell therapy for leukemia) and <strong>Zolgensma<\/strong> (a one-time gene therapy for spinal muscular atrophy).<\/li>\n\n\n\n<li><strong>Massive R&amp;D Infrastructure:<\/strong> The company reinvests roughly <strong>$9\u201310 billion annually<\/strong> into clinical research, running hundreds of global trials that drive basic science into commercial production.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">2. World Without Novartis: The Counterfactual<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">If Novartis had never existed\u2014or vanished overnight\u2014the ripple effects would touch medicine, historical science, and global corporate structure.<\/p>\n\n\n\n<pre class=\"wp-block-preformatted\"> <code>      [Historical Mergers: Ciba-Geigy + Sandoz (1996)]\n                               \u2502\n                \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n                \u25bc                             \u25bc\n   If Novartis Didn't Exist       If Sandoz\/Ciba Never Existed\n   (Therapies absorbed elsewhere)   (Fundamental chemical\/pharma delays)\n<\/code><\/pre>\n\n\n\n<h3 class=\"wp-block-heading\">Immediate Medical Gaps<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Delayed Breakthroughs:<\/strong> While another multinational pharma company might eventually have synthesized similar molecules, the timeline for revolutionary target drugs like <strong>imatinib (Gleevec)<\/strong> would have been delayed by years or decades. Thousands of CML patients who survived the early 2000s onwards would have faced significantly higher mortality.<\/li>\n\n\n\n<li><strong>Gene Therapy Bottlenecks:<\/strong> Developing ultra-expensive, complex modalities like CAR-T cell manufacturing requires deep balance sheets. Without Novartis absorbing initial commercial losses and building cold-chain supply infrastructure, gene therapy adoption in clinical oncology would be further behind.<\/li>\n\n\n\n<li><strong>Global Access Gaps:<\/strong> Novartis runs major non-profit and access programs, such as its long-standing multi-drug therapy donation for leprosy (in partnership with the WHO), which has helped cure over 18 million leprosy patients worldwide.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis was formed in 1996 through the merger of <strong>Ciba-Geigy<\/strong> and <strong>Sandoz<\/strong>\u2014two Swiss chemical and pharmaceutical giants whose roots traced back to the 19th-century Rhine Valley dye industry.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The Sandoz Legacy:<\/strong> Albert Hofmann discovered LSD at Sandoz in 1938. Sandoz also commercialized cyclosporine, the immunosuppressant that made routine organ transplantation viable across modern surgery.<\/li>\n\n\n\n<li><strong>Market Consolidation:<\/strong> Had the 1996 merger not occurred, European drug development would likely be split among smaller regional players, or acquired by US\/UK giants like Pfizer, Merck, or AstraZeneca.<\/li>\n\n\n\n<li><strong>The Swiss Economic Anchor:<\/strong> Basel\u2019s identity as a global life sciences powerhouse relies heavily on the dual presence of Roche and Novartis. Without Novartis, Switzerland&#8217;s trade balance and corporate tax base would lose one of its largest net exporters.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"547\" src=\"https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-40.png\" alt=\"\" class=\"wp-image-1945\" srcset=\"https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-40.png 1024w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-40-300x160.png 300w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-40-768x410.png 768w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-40-500x267.png 500w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">The Verdict<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis is indispensable to the global biomedical system. While its drug pricing strategies and patent protection models spark standard industry debate, its ability to finance billion-dollar clinical trials and commercialize complex therapies means a world without Novartis would have fewer targeted cancer treatments, slower gene therapy adoption, and a noticeably lower global standard of care over the last 30 years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Reint Jelger: Do you think that when Jesus comes back and heals all the people, Novartis might loose in market capitalization? (Just a joke)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Google Gemini: Haha, if we take that thought experiment to its logical conclusion, Novartis\u2014along with the entire $1.6 trillion global pharmaceutical sector\u2014would be looking at the ultimate market disruption!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If a sudden return of Jesus instantly erased all chronic illness, genetic disorders, and disease worldwide, the fundamental unit of demand driving pharmaceutical revenues would vanish overnight.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Here is how that &#171;market crash&#187; would realistically play out on the balance sheet:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Massive Revenue Wipeout:<\/strong> Novartis\u2019s top revenue drivers\u2014like <strong>Entresto<\/strong> (heart failure), <strong>Cosentyx<\/strong> (psoriasis\/arthritis), and <strong>Kesimpta<\/strong> (multiple sclerosis)\u2014rely on long-term daily or monthly therapeutic management. If no one has heart failure or auto-immune inflammation anymore, annual revenues (currently around $45\u2013$50 billion) would plunge near zero.<\/li>\n\n\n\n<li><strong>Write-Off of $10 Billion Annual R&amp;D:<\/strong> The pipeline of drug discovery would become obsolete overnight. Immense clinical trial infrastructure, laboratories, and intellectual property portfolios would be written off as stranded assets.<\/li>\n\n\n\n<li><strong>The &#171;Leprosy Parallel&#187;:<\/strong> Ironically, Novartis has spent decades donating multi-drug treatments to help the WHO eliminate leprosy globally. In this scenario, <em>every<\/em> disease gets the &#171;leprosy elimination&#187; treatment instantly, rendering their main commercial engines unnecessary.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">What Would Be Left?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Unless Novartis quickly pivoted its advanced biotechnology, cell labs, and cold-chain supply networks into wellness, longevity research, or pure bioscience, its market capitalization would fall by well over 90\u201395%.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It would be the first time in corporate history where a company&#8217;s market cap collapses not because its product failed, but because its mission was completely\u2014and divinely\u2014rendered obsolete!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Reint Jelger: What do you think the Baarda.ch audience should know about Novartis if they would be contemplating buying stock in Novartis?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Google Gemini: For analytical readers evaluating international blue chips, corporate restructurings, and macro capital allocation, <strong>Novartis AG (SIX: NOVN \/ NYSE: NVS)<\/strong> presents a textbook case study in corporate specialization, capital efficiency, and R&amp;D capital allocation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">When evaluating Novartis as an investment candidate, readers should examine five structural themes:<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. Pure-Play Transformation: The Sandoz Spin-off &amp; Portfolio Streamlining<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Over the past decade, Novartis transitioned from a diversified healthcare conglomerate into a <strong>pure-play innovative medicines company<\/strong>.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The Sandoz Demerger:<\/strong> The completion of the Sandoz (generics and biosimilars division) tax-free spin-off was a major structural milestone.<\/li>\n\n\n\n<li><strong>Strategic Takeaway:<\/strong> By divesting lower-margin generic operations and consumer healthcare assets (e.g., historical joint ventures with GSK and holdings in Roche), Novartis traded volume stability for <strong>higher gross margins and cleaner capital allocation<\/strong>. The risk profile has shifted from operational efficiency in generics to pipeline execution in novel therapeutics.<\/li>\n<\/ul>\n\n\n\n<pre class=\"wp-block-preformatted\"> <code>      [Historical Conglomerate]\n       (Pharma + Generics\/Sandoz + Consumer Health + Roche Stake)\n                               \u2502\n                               \u25bc [Strategic Divestment &amp; Spin-offs]\n       [Pure-Play Innovative Medicines Platform]\n       (Oncology, Targeted Radioligands, Gene Therapies, Immunology)\n<\/code><\/pre>\n\n\n\n<h2 class=\"wp-block-heading\">2. Advanced Modality Concentration (Moats vs. Patent Cliff)<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis trades heavy exposure to traditional small-molecule drugs for cutting-edge, high-barrier platforms:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Radioligand Therapies (RLT) &amp; Gene Therapy:<\/strong> Through assets like <strong>Pluvicto<\/strong> (prostate cancer) and <strong>Zolgensma<\/strong> (SMA), Novartis built expensive, hard-to-replicate cold-chain and manufacturing infrastructure that acts as a structural competitive moat.<\/li>\n\n\n\n<li><strong>Patent Expirations (&#171;Loss of Exclusivity&#187;):<\/strong> Like all mega-cap pharma, investors must track the revenue bridge as blockbusters face generic competition later in the decade (e.g., <strong>Entresto<\/strong> patent litigation challenges). Readers need to assess whether late-stage Phase III readouts (such as <strong>ianalumab<\/strong> or <strong>remibrutinib<\/strong>) can scale fast enough to offset impending revenue drop-offs.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">3. Financial Mechanics: P\/E Multiple, Dividend Policy &amp; Buybacks<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">From a fundamental analysis perspective, Novartis functions as a core European quality-yield asset:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation &amp; Multiples:<\/strong> Historically trades at a forward P\/E around 15x\u201317x, often at a discount to US peers (like Eli Lilly or Merck) due to lower exposure to high-growth obesity markets (GLP-1s), but aligned with top-tier European life science multiples.<\/li>\n\n\n\n<li><strong>Dividend Track Record:<\/strong> Novartis has maintained continuous annual dividend increases in Swiss Francs (CHF) for nearly three decades, offering a forward dividend yield hovering around <strong>2.8% to 3.1%<\/strong>. Morningstar<\/li>\n\n\n\n<li><strong>FX Consideration for Non-CHF Investors:<\/strong> Because dividends and capital base are anchored in Swiss Francs (CHF), investors buying via ADRs (NVS) or outside Switzerland experience an inherent foreign exchange overlay\u2014often benefiting from the long-term structural strength of the CHF against the EUR or USD.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">4. R&amp;D Capital Intensity &amp; Margin Discipline<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis reinvests roughly <strong>$9\u201310 billion annually<\/strong> into R&amp;D (~20% of net sales).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The primary metric for tracking operational efficiency post-restructuring is its <strong>Core Operating Margin<\/strong>, which management has targeted in the <strong>40%+ range<\/strong>.<\/li>\n\n\n\n<li>Investors should monitor whether cost-reduction initiatives and streamlined corporate overhead translate into expanding free cash flow (FCF) conversion.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">5. Key Decision Checklist for Investors<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Bull Case<\/th><th>Primary Risk Factors \/ Bear Case<\/th><\/tr><\/thead><tbody><tr><td>High-margin focus on targeted modalities (RLT, siRNA, CAR-T).<\/td><td>Patent expiry headwinds on current core revenue drivers.<\/td><\/tr><tr><td>Consistent CHF dividend growth + active share buyback programs.<\/td><td>Regulatory headwinds (e.g., US Inflation Reduction Act price negotiations).<\/td><\/tr><tr><td>Capital discipline following non-core asset divestments.<\/td><td>Clinical trial failures in late-stage Phase III pipeline assets.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-39.png\" alt=\"\" class=\"wp-image-1944\" srcset=\"https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-39.png 1024w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-39-300x168.png 300w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-39-768x429.png 768w, https:\/\/baarda.ch\/wp-content\/uploads\/2026\/11\/afbeelding-39-500x279.png 500w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Google Gemini: Novartis is the third-largest pharmaceutical company in Europe by market value (behind Novo Nordisk and Roche) and consistently ranks among the top 10 globally. With annual revenues around $45\u201350 billion and a market capitalization exceeding $200 billion, it &hellip; <a href=\"https:\/\/baarda.ch\/?p=1943\">Weiterlesen <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1943","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/baarda.ch\/index.php?rest_route=\/wp\/v2\/posts\/1943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/baarda.ch\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/baarda.ch\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/baarda.ch\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/baarda.ch\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1943"}],"version-history":[{"count":1,"href":"https:\/\/baarda.ch\/index.php?rest_route=\/wp\/v2\/posts\/1943\/revisions"}],"predecessor-version":[{"id":1947,"href":"https:\/\/baarda.ch\/index.php?rest_route=\/wp\/v2\/posts\/1943\/revisions\/1947"}],"wp:attachment":[{"href":"https:\/\/baarda.ch\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/baarda.ch\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/baarda.ch\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}